Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies
British Journal of Clinical Pharmacology · 2023
DOI: 10.1111/bcp.15683 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Rashmi Mehta und 10 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ViiV Healthcare, Janssen Research and Development.
Abstract (Originalsprache)
Aim
SWORD‐1 and SWORD‐2 phase 3 studies concluded that switching virologically suppressed participants with HIV‐1 from their current three‐ or four‐drug antiretroviral regimen (CAR) to the two‐drug regimen of once‐daily dolutegravir (DTG, 50 mg) and rilpivirine (RPV, 25 mg) was safe, well tolerated and noninferior for maintaining HIV‐1 suppression at week 48 and highly efficacious to week 148. A secondary objective was to characterize drug exposure and exposure‐efficacy/safety relationships.
Methods
Adults with plasma HIV‐1 RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK, Durham, North Carolina, USA.
- GSK, Upper Providence, Pennsylvania, USA.
- GSK, Brentford, UK.
- GSK, Stevenage, UK.
- ViiV Healthcare, Brentford, UK.
- ViiV Healthcare, Durham, North Carolina, USA.
Förderung
- ViiV Healthcare
- Janssen Research and Development
Zitieren
APA
Mehta, R., Lagishetty, C. V., Angelis, K., Aylott, A., Kahl, L., Blair, L., Matthews, J., Wynne, B., Crauwels, H., Underwood, M., & Adkison, K. K. (2023). Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15683
Vancouver
Mehta R, Lagishetty CV, Angelis K, Aylott A, Kahl L, Blair L, et al. Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15683
BibTeX
@article{Mehta2023,
author = {Mehta, Rashmi and Lagishetty, Chakradhar V and Angelis, Konstantinos and Aylott, Alicia and Kahl, Lesley and Blair, Libby and Matthews, Jessica and Wynne, Brian and Crauwels, Herta and Underwood, Mark and Adkison, Kimberly K},
title = {Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1111/bcp.15683}
}
EUVIMED